Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.

Devonshire V, Phillips R, Wass H, Da Roza G, Senior P.

J Neurol. 2018 Nov;265(11):2494-2505. doi: 10.1007/s00415-018-8822-y. Epub 2018 Mar 10. Review.

2.
3.

Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.

Lapierre Y, O'Connor P, Devonshire V, Freedman MS, Kremenchutzky M, Yeung M, Schecter R.

Can J Neurol Sci. 2016 Mar;43(2):278-83. doi: 10.1017/cjn.2015.325. Epub 2016 Jan 25.

PMID:
26890887
4.

Health-related quality of life in patients with longstanding 'benign multiple sclerosis'.

Bueno AM, Sayao AL, Yousefi M, Devonshire V, Traboulsee A, Tremlett H.

Mult Scler Relat Disord. 2015 Jan;4(1):31-8. doi: 10.1016/j.msard.2014.09.211. Epub 2014 Oct 7.

PMID:
25787050
5.

MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary.

Selchen D, Bhan V, Blevins G, Devonshire V, Duquette P, Grand'Maison F, Kremenchutzky M, Lapierre Y, Li D, von Riedemann SJ, Freedman M.

Neurology. 2012 Dec 4;79(23 Suppl 2):S1-15. doi: 10.1212/WNL.0b013e318277d144.

PMID:
23212280
6.
7.

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group.

Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22494956
8.

The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.

Sayao AL, Bueno AM, Devonshire V, Tremlett H; UBC MS Clinic Neurologists.

Mult Scler. 2011 Nov;17(11):1375-83. doi: 10.1177/1352458511410343. Epub 2011 Jun 15.

PMID:
21677023
9.

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.

Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; GAP Study Group.

Eur J Neurol. 2011 Jan;18(1):69-77. doi: 10.1111/j.1468-1331.2010.03110.x.

PMID:
20561039
10.

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.

Devonshire V, Arbizu T, Borre B, Lang M, Lugaresi A, Singer B, Verdun di Cantogno E, Cornelisse P.

BMC Neurol. 2010 Apr 30;10:28. doi: 10.1186/1471-2377-10-28.

11.

Impact of multiple sclerosis relapses on progression diminishes with time.

Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y; UBC Neurologists.

Neurology. 2009 Nov 17;73(20):1616-23. doi: 10.1212/WNL.0b013e3181c1e44f. Epub 2009 Nov 4.

12.

Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.

Tremlett H, Zhao Y, Devonshire V; UBC Neurologists.

J Neurol. 2009 Mar;256(3):374-81. doi: 10.1007/s00415-009-0039-7. Epub 2009 Mar 18.

PMID:
19308306
13.

Escalating immunotherapy of multiple sclerosis.

Rieckmann P, Traboulsee A, Devonshire V, Oger J.

Ther Adv Neurol Disord. 2008 Nov;1(3):181-92. doi: 10.1177/1756285608098359.

14.

Defining the natural history of MS: the need for complete data and rigorous definitions.

Tremlett H, Zhao Y, Devonshire V.

Mult Scler. 2008 Sep;14(8):1142-3; author reply 1144-7. doi: 10.1177/1352458508095131. Epub 2008 Aug 13. No abstract available.

PMID:
18701573
15.

The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics.

O'Connor P, Devonshire V; Canadian Network of MS Clinic.

Can J Neurol Sci. 2008 May;35(2):127-32. English, French. No abstract available.

PMID:
18574923
16.

Relapses in multiple sclerosis are age- and time-dependent.

Tremlett H, Zhao Y, Joseph J, Devonshire V; UBCMS Clinic Neurologists.

J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1368-74. doi: 10.1136/jnnp.2008.145805. Epub 2008 Jun 5.

PMID:
18535026
17.

Natural history of secondary-progressive multiple sclerosis.

Tremlett H, Yinshan Zhao, Devonshire V.

Mult Scler. 2008 Apr;14(3):314-24. doi: 10.1177/1352458507084264. Epub 2008 Jan 21.

PMID:
18208898
18.

Longitudinal follow-up of "benign" multiple sclerosis at 20 years.

Sayao AL, Devonshire V, Tremlett H.

Neurology. 2007 Feb 13;68(7):496-500.

PMID:
17296915
19.

Is late-onset multiple sclerosis associated with a worse outcome?

Tremlett H, Devonshire V.

Neurology. 2006 Sep 26;67(6):954-9.

PMID:
17000960
20.

Does the season or month of birth influence disease progression in multiple sclerosis?

Tremlett HL, Devonshire VA.

Neuroepidemiology. 2006;26(4):195-8. Epub 2006 Mar 28.

PMID:
16567947
21.

Disability progression in multiple sclerosis is slower than previously reported.

Tremlett H, Paty D, Devonshire V.

Neurology. 2006 Jan 24;66(2):172-7.

PMID:
16434648
22.

The natural history of primary progressive MS in British Columbia, Canada.

Tremlett H, Paty D, Devonshire V.

Neurology. 2005 Dec 27;65(12):1919-23.

PMID:
16380613
23.

Remission of multiple sclerosis post-liver transplantation.

Yoshida EM, Devonshire VA, Prout AJ.

Can J Neurol Sci. 2004 Nov;31(4):539-41.

PMID:
15595263
24.

The immune system and hormones: review and relevance to pregnancy and contraception in women with MS.

Devonshire V, Duquette P, Dwosh E, Guimond C.

Int MS J. 2003 Jun;10(2):44-50. Review.

PMID:
14561382
25.

Early onset multiple sclerosis: a longitudinal study.

Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D; University of British Columbia MS Clinic Neurologists.

Neurology. 2002 Oct 8;59(7):1006-10.

PMID:
12370453
26.

Genetic susceptibility to MS: a second stage analysis in Canadian MS families.

Dyment DA, Willer CJ, Scott B, Armstrong H, Ligers A, Hillert J, Paty DW, Hashimoto S, Devonshire V, Hooge J, Kastrukoff L, Oger J, Metz L, Warren S, Hader W, Power C, Auty A, Nath A, Nelson R, Freedman M, Brunet D, Paulseth JE, Rice G, O'Connor P, Duquette P, Lapierre Y, Francis G, Bouchard JP, Murray TJ, Bhan V, Maxner C, Pryse-Phillips W, Stefanelli M, Sadovnick AD, Risch N, Ebers GC.

Neurogenetics. 2001 Jul;3(3):145-51.

PMID:
11523565
27.

Continuous intrathecal pump infusion of baclofen with antibiotic drugs for treatment of pump-associated meningitis. Case report.

Zed PJ, Stiver HG, Devonshire V, Jewesson PJ, Marra F.

J Neurosurg. 2000 Feb;92(2):347-9.

PMID:
10659025

Supplemental Content

Loading ...
Support Center